The European Centre for Disease Prevention and Control (ECDC) reports that the burden of healthcare-associated C. difficile infection (CDIs) in acute care hospitals in the EU/EEA was estimated at 123.997 cases annually1. In the ECDC point prevalence survey of healthcare-associated infections (HAIs) and antimicrobial use in European acute care hospitals 2011-2012, C. difficile was the 8th most frequently detected microorganism among HAIs. Using a conservative figure of 3% attributable mortality, the number of deaths occurring as the direct consequence of healthcare-associated CDI can be estimated at 3.700 per year in the EU/EEA.
1. ECDC SURVEILLANCE REPORT Point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals 2011–2012
Why to choose it
A high-throughput, simplified workflow without DNA isolation that provides results in about an hour.
For use on
Rapid results and high-throughput
The SimplexaTM C. difficile Universal Direct assay allows you to perform up to 94 patient samples per run with results in about 1 hour.
High quality data that you can trust
The SimplexaTM C. difficile Universal Direct assay delivers diagnostic confidence with greater than 99% positive agreement.
|Reference PCR||N||Positive||Negative||% Agreement|
|Reference PCRPositive||N110||Positive109||Negative1||% Agreement99.1% (109/110)
95% CI: 95-99.8%
|Reference PCRNegative||N79||Positive7||Negative72||% Agreement91.1% (72/79)
95% CI: 82.8-95.6%
SimplexaTM C. difficile Universal Direct
|Code MOL2975||Reactions 100|
Do you want to place an order or request a trial?Discover More